117
Participants
Start Date
December 4, 2023
Primary Completion Date
March 15, 2028
Study Completion Date
March 15, 2028
Ropeginterferon alfa-2b (BESREMi®)
Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.
Ordensklinikum Linz GmbH Elisabethinen Hospital, Department of Internal Medicine I - Hemato-Oncology, Linz
University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology, Debrecen
Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology), Innsbruck
University Hospital Graz, Department of Internal Medicine, Clinical Department of Hematology, Graz
University Hospital Kralovske Vinohrady, Clinic of Internal Hematology, Prague
University Hospital City of Health and Science of Turin - Hospital Molinette, Complex Structure of Hematology - U, Turin
General Hospital of Athens Alexandra, Therapeutic Clinic, Department of Therapeutics, Athens
University Hospital Ramon y Cajal, Hematology Service, Madrid
Morales Meseguer University General Hospital, Murcia
Hannover Medical School, Clinic for haematology, haemostaseology, oncology and stem cell transplantation, Hanover
Johannes Wesling Hospital Minden, Department of Oncology and Hematology, Minden
Bordeaux University Hospital, Haut-Leveque Hospital, Pessac
Polyclinic S. Orsola-Malpighi, Bologna
Careggi University Hospital, Department of Hematology, Florence
University Hospital Aachen, Clinic of Oncology, Hematology and Stem Cell Transplantation (Medical Clinic IV), Aachen
University Hospital Mannheim, Medical Clinic III, Hematology and Internistic Oncology, Mannheim
Saint-Louis Hospital, Department of Adult Hematology, Paris
Centre Hospitalier Universitaire De Poitiers, Poitiers
University Hospital Ulm, Center for Internal Medicine, Clinic of Internal Medicine III, Department of Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm
"Prof. Dr. Ion Chiricuta Institute of Oncology, Hematology Department", Cluj-Napoca
Onco Card Srl, Brasov
Iasi Regional Institute of Oncology, Department of Hematology, Iași
Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology, Vienna
University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno
University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology, Halle
"University General Hospital Attikon", Athens
Semmelweis University, Department of Internal Medicine and Haematology, Division of Hematology, Budapest
Umberto I Polyclinic of Rome, Rome
"University Polyclinic Foundation Agostino Gemelli - IRCCS, Service of Hematology", Rome
University Teaching Centre, Hematology and Transplantology Clinic, Gdansk
Pratia Oncology Katowice, Katowice
Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department, Krakow
Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz, Department of Hematooncology with Subdivision of Daytime Chemotherapy, Lodz
Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation, Crişan
University Hospital Germans Trias i Pujol, Badalona
Hospital Clinic of Barcelona, Department of Hematology, Barcelona
Lead Sponsor
AOP Orphan Pharmaceuticals AG
INDUSTRY